Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Ryan Weis

KeyBanc Capital Markets · covers Basic Materials

Period: Reporting periods mapped to calendar 2024 Q4 – 2025 Q3 (4 quarters; questions recorded in 3).

Limited coverage. Only 6 questions of coverage. Treat these numbers as directional — sample too small for reliable averages.
Questions
6on tracked calls
Challenge rate
0%none of 6 questionsLimited sample
Companies
3questioned at least once
Reporting periods
3with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 6 of 6 questions from 3 companies

PPGPPG Industries3 questions · 3 reporting periods · 0 of 3 challenging
PPG company page →

Calendar 2025 Q3

Can you maybe just help us understand the differences in what's going on in the U.S. market versus maybe what's going on in Europe right now?

DemandCompetitive DynamicsTranscript · FY2025 Q3 →
Show response

Morales explained U.S. insurance premium surge (up significantly) vs Europe (claims down only mid-single digits, tracking accident rates). Knavish noted share gains in both U.S. and Europe, with #1 and #2 players winning from smaller competitors. PPG uniquely re-expanding revenue pie through subscription-based digital tools.

Calendar 2025 Q2

I think there's been a lot of news circulating kind of in the last couple of weeks just around potentially some elevated inventories, the end of price cutting wars

DemandGeographic ExpansionTranscript · FY2025 Q2 →
Show response

Knavish noted China doing better than rest of world on production. PPG's #1 position with the largest EV player (BYD implied), 1 out of 3 cars globally produced in China. Morales added China exports up ~10% through H1, driving production.

Calendar 2024 Q4

So wondering what you're hearing from customers at this stage and kind of what your expectation is here in 2025

DemandGeographic ExpansionTranscript · FY2024 Q4 →
Show response

Knavish highlighted strong China auto retail (+19% Q4), share gains with domestic OEMs including the largest, and EVs at 37% of China production. Government stimulus expected to continue.

DDDuPont2 questions · 1 reporting period · 0 of 2 challenging
DD company page →

Calendar 2025 Q3

just kind of wondering what your outlook is? I know it's still early kind of getting into '26

DemandMacroeconomicTranscript · FY2025 Q3 →
Show response

Franzen noted Shelter held flat with market in 2024, expecting -4% organic in 2025. Industry reports suggest H2 2026 improvement. Even getting to flat would have nice impact on total organic growth.

I was hoping to kind of focus on what you currently have and especially in the healthcare business

DemandRevenue GrowthTranscript · FY2025 Q3 →
Show response

Koch reported strong growth across all Healthcare sub-segments: Liveo (biopharma), med packaging, and med device. New CDMO leader joining from external hire. Healthcare & Water combined mid- to high single-digit full year growth.

CTVACorteva1 question · 1 reporting period · 0 of 1 challenging
CTVA company page →

Calendar 2024 Q4

what percentage of raw materials would be at risk kind of to the potential tariffs in Canada and Mexico

Trade TariffsSupply ChainTranscript · FY2024 Q4 →
Show response

Chuck framed tariffs as primarily a CP issue. Enlist and Spinosyns manufactured exclusively in US, making Corteva a net exporter. China is ~2% of COGS, 80% multi-sourced.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
PPG PPG Industries30%none of 3 questions
DD DuPont2—Rate withheld: fewer than 3 questions
CTVA Corteva1—Rate withheld: fewer than 3 questions
  • PPG
    PPG Industries · 3 questions
    0%none of 3 questions
  • DD
    DuPont · 2 questions
    —rate withheld: under 3 questions
  • CTVA
    Corteva · 1 question
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2024 Q420%none of 2 questions2
2025 Q1No questions recorded——
2025 Q210%none of 1 question1
2025 Q330%none of 3 questions2
  1. 2024 Q42 questions · challenge rate 0% (none of 2 questions) · 2 companies
  2. 2025 Q1No questions recorded
  3. 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company
  4. 2025 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies

Topics

Topics tagged on this analyst’s questions.

  • Demand5
  • Geographic Expansion2
  • Macroeconomic1
  • Revenue Growth1
  • Competitive Dynamics1
  • Trade Tariffs1
  • Supply Chain1